| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
Monomethyl auristatin E intermediate-1 does not have a defined pharmacological target itself, as it is a synthetic intermediate rather than a therapeutic agent. Its purpose is to serve as a precursor for the synthesis of MMAE, which is a microtubule/tubulin inhibitor. MMAE exerts its anti-cancer activity by inhibiting microtubule polymerization, leading to cell cycle arrest and apoptosis. The intermediate is a building block for the cytotoxic payload of ADCs.
|
|---|---|
| ln Vitro |
The intermediate itself does not exhibit in vitro biological activity, as it is a chemical precursor rather than a bioactive molecule. Its utility lies in its chemical reactivity for the synthesis of MMAE, which is a potent microtubule/tubulin inhibitor with anti-cancer activity. MMAE is widely utilized as the cytotoxic component of antibody-drug conjugates. The intermediate is a high-purity reagent (≥98%) used in chemical synthesis.
|
| ln Vivo |
No in vivo activity is reported for this intermediate, as it is not intended for direct therapeutic use. Its role is as a precursor in the synthesis of MMAE, which has demonstrated anti-cancer activity in preclinical and clinical studies. MMAE-containing ADCs are used in cancer therapy to deliver the cytotoxic payload specifically to tumor cells. The intermediate itself is not administered to animals or humans.
|
| Enzyme Assay |
Non-cellular assays are not applicable for this compound, as it is a chemical intermediate and is not evaluated in pharmacological binding assays. Its characterization typically involves analytical methods such as NMR, HPLC, and mass spectrometry to confirm structure and purity. The compound's identity and purity are verified using standard organic chemistry analytical techniques. No receptor binding or enzyme inhibition assays are performed with this intermediate.
|
| Cell Assay |
Cell-based assays are not performed with this intermediate as a test article. It is used in the chemical synthesis of MMAE, which is then evaluated for biological activity in cell-based assays. MMAE's anti-cancer activity is assessed in cancer cell lines by measuring cell viability, proliferation, and apoptosis. The intermediate itself is not tested in cell-based assays, as it is a synthetic precursor rather than a pharmacologically active compound.
|
| Animal Protocol |
In vivo animal studies are not conducted with this intermediate as a primary test agent. It is used in the chemical synthesis of MMAE, which is then evaluated in animal models for anti-cancer efficacy. MMAE-containing ADCs are tested in xenograft models to assess tumor growth inhibition and survival. The intermediate itself is not administered to animals.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data are not applicable for this compound, as it is a synthetic intermediate rather than a drug candidate. Its physicochemical properties include a LogP of 3.56 and solubility in DMSO at 50 mg/mL. The compound is stored under nitrogen, away from moisture. No pharmacokinetic parameters have been characterized for this intermediate.
|
| Toxicity/Toxicokinetics |
No toxicity data are reported for this intermediate. As a chemical reagent, it should be handled with standard laboratory safety precautions. The compound is for research use only and is not for human use. Its safety profile has not been evaluated in humans. Proper personal protective equipment should be used during handling.
|
| References |
[1]. Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87.
|
| Additional Infomation |
Monomethyl auristatin E intermediate-1 is a research chemical, not an approved drug. It is a critical intermediate in the synthesis of Monomethyl auristatin E (MMAE), a microtubule/tubulin inhibitor with anti-cancer activity. MMAE is extensively used as the cytotoxic component of antibody-drug conjugates (ADCs). The intermediate is available as a high-purity research reagent (≥98%) and is used in the development of ADC-based cancer therapeutics. It is not intended for human therapeutic use.
|
| Molecular Formula |
C14H30CLNO3
|
|---|---|
| Molecular Weight |
295.85
|
| Exact Mass |
295.191
|
| CAS # |
120205-48-3
|
| PubChem CID |
14730240
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.56
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
19
|
| Complexity |
248
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
Cl[H].O(C([H])([H])[H])[C@]([H])(C([H])([H])C(=O)OC(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])[C@]([H])([C@@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])[H])N([H])C([H])([H])[H]
|
| InChi Key |
JRXGCIIOQALIMZ-LWEGJDAASA-N
|
| InChi Code |
InChI=1S/C14H29NO3.ClH/c1-8-10(2)13(15-6)11(17-7)9-12(16)18-14(3,4)5;/h10-11,13,15H,8-9H2,1-7H3;1H/t10-,11+,13-;/m0./s1
|
| Chemical Name |
tert-butyl (3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~169.0 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.45 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3801 mL | 16.9005 mL | 33.8009 mL | |
| 5 mM | 0.6760 mL | 3.3801 mL | 6.7602 mL | |
| 10 mM | 0.3380 mL | 1.6900 mL | 3.3801 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
